

# Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/H4BA0E626FFFEN.html>

Date: August 2022

Pages: 151

Price: US\$ 3,500.00 (Single User License)

ID: H4BA0E626FFFEN

## Abstracts

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

### SUMMARY

According to the recently published report 'Histone Deacetylase 6 - Drugs In Development, 2022'; Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) pipeline Target constitutes close to 53 molecules. Out of which approximately 44 molecules are developed by companies and remaining by the universities/institutes.

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Histone deacetylase 6 is an enzyme encoded by the HDAC6 gene. Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases plays a central role in microtubule-dependent cell motility via deacetylation of tubulin. It is involved in the MTA1-mediated epigenetic regulation of ESR1 expression in breast cancer. It plays a key role in the degradation of misfolded proteins. It acts as an adapter that recognizes polyubiquitinated misfolded proteins and target them to the aggresome, facilitating their clearance by autophagy.

The report 'Histone Deacetylase 6 - Drugs In Development, 2022' outlays comprehensive information on the Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 6, 4, 1, 27 and 6 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 7 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Genetic Disorders, Immunology, Toxicology, Respiratory, Cardiovascular, Gastrointestinal, Infectious Disease, Musculoskeletal Disorders and Undisclosed which include indications Multiple Myeloma (Kahler Disease), Melanoma, Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Alzheimer's Disease, Breast Cancer, Charcot-Marie-Tooth Disease Type II, Charcot-Marie-Tooth Disease, Chemotherapy Induced Peripheral Neuropathy, Colorectal Cancer, Diffuse Large B-Cell Lymphoma, Glioblastoma Multiforme (GBM), Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Multiple Sclerosis, Non-Small Cell Lung Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Triple-Negative Breast Cancer (TNBC), Chronic Lymphocytic Leukemia (CLL), Colon Cancer, Follicular Lymphoma, Idiopathic Pulmonary Fibrosis, Leukemia, Mantle Cell Lymphoma, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Rheumatoid Arthritis, Squamous Cell Carcinoma, Systemic Lupus Erythematosus, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Adenoid Cystic Carcinoma (ACC), Amyotrophic Lateral Sclerosis, Anal Cancer, Anaplastic Astrocytoma, Autoimmune Disorders, B-Cell Non-Hodgkin Lymphoma, Basal Cell Carcinoma (Basal Cell Epithelioma), Bile Duct Cancer (Cholangiocarcinoma), Burkitt Lymphoma, Cervical Cancer, Charcot-Marie-Tooth Disease Type I A, CNS Lymphoma, Crohn's Disease (Regional Enteritis), Cutaneous T-Cell Lymphoma, Diabetic Neuropathic Pain, Diastolic Heart Failure, Dilated Cardiomyopathy, Distal Symmetric Polyneuropathy, Fibrosis, Gastric Cancer, Gliosarcoma, Head And Neck Cancer Squamous Cell Carcinoma, High-Grade Glioma, Human Papillomavirus (HPV) Associated Cancer, Huntington Disease, Liver Cancer, Lung Adenocarcinoma, Lupus Nephritis, Lymphoma, Marginal Zone B-cell Lymphoma, Metastatic Melanoma, Mycosis Fungoides, Myelodysplastic Syndrome, Myeloproliferative Disorders, Neuroblastoma, Neuroendocrine Tumors, Neurology,

Neuropathic Pain (Neuralgia), Non-Hodgkin Lymphoma, Non-Small Cell Lung Carcinoma, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Pediatric Diffuse Intrinsic Pontine Glioma, Penile Cancer, Polycystic Kidney Disease, Rectal Cancer, Recurrent Medulloblastoma, Rett Syndrome, Sepsis, Small-Cell Lung Cancer, Systemic Sclerosis (Scleroderma), Tauopathies, Ulcerative Colitis, Unspecified, Unspecified B-Cell Lymphomas, Unspecified Cancer and Vulvar Cancer.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98)

The report reviews Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects

The report assesses Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics

## REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Overview

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Companies Involved in Therapeutics Development

Annji Pharmaceutical Co Ltd

ATP Biopharm

Augustine Therapeutics

Avstera Therapeutics Inc

Beijing Konruns Pharmaceutical Co Ltd

Bristol-Myers Squibb Co

Chong Kun Dang Pharmaceutical Corporation

Convalife

CStone Pharmaceuticals Co Ltd

Curis Inc

Eikonizo Therapeutics Inc

Guangdong Zhongsheng Pharmaceutical Co Ltd

Hillstream BioPharma Inc

Jubilant Therapeutics Inc

Kancera AB

Karus Therapeutics Ltd

KYAN Therapeutics Inc

Medivir AB

Merck & Co Inc

Mycovia Pharmaceuticals Inc

OnKure Inc

Oryzon Genomics SA

Quimatrix SL

Shuttle Pharmaceuticals Inc

SK Biopharmaceuticals Co Ltd

Starwise Therapeutics LLC

Suzhou GenHouse Pharmaceutical Co Ltd

Tenaya Therapeutics Inc

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Drug Profiles

ACY-1083 - Drug Profile

Product Description

Mechanism Of Action

History of Events

ACY-738 - Drug Profile

Product Description

Mechanism Of Action

History of Events

ACY-775 - Drug Profile

Product Description

Mechanism Of Action

History of Events

ADV-300 - Drug Profile

Product Description

Mechanism Of Action

AJ-302 - Drug Profile

Product Description

Mechanism Of Action

History of Events

AJ-303 - Drug Profile

Product Description

Mechanism Of Action

History of Events

AVS-100 - Drug Profile

Product Description

Mechanism Of Action

History of Events

C-1A - Drug Profile

Product Description  
Mechanism Of Action  
citarinostat - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
CKD-504 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
CKD-506 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
CKD-510 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
CKD-L - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
CS-3003 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
CVL-608 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
CX-1026 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
EKZ-001 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
fimepinostat - Drug Profile  
Product Description



Mechanism Of Action

History of Events

GH-36 - Drug Profile

Product Description

Mechanism Of Action

HDAC6 - Drug Profile

Product Description

Mechanism Of Action

HSB-510 - Drug Profile

Product Description

Mechanism Of Action

History of Events

JBI-097 - Drug Profile

Product Description

Mechanism Of Action

History of Events

JBI-802 - Drug Profile

Product Description

Mechanism Of Action

History of Events

KA-2507 - Drug Profile

Product Description

Mechanism Of Action

History of Events

KAN-0440262 - Drug Profile

Product Description

Mechanism Of Action

History of Events

KYAN-001 - Drug Profile

Product Description

Mechanism Of Action

History of Events

MPT-0B291 - Drug Profile

Product Description

Mechanism Of Action

MPT-0G211 - Drug Profile

Product Description

Mechanism Of Action

History of Events



**Nexturastat A - Drug Profile**

Product Description

Mechanism Of Action

**QTX-125 - Drug Profile**

Product Description

Mechanism Of Action

History of Events

**QTX-153 - Drug Profile**

Product Description

Mechanism Of Action

History of Events

**remetinostat - Drug Profile**

Product Description

Mechanism Of Action

History of Events

**ricolinostat - Drug Profile**

Product Description

Mechanism Of Action

History of Events

**RTSV-5 - Drug Profile**

Product Description

Mechanism Of Action

History of Events

**SE-7552 - Drug Profile**

Product Description

Mechanism Of Action

History of Events

**SKLB-23bb - Drug Profile**

Product Description

Mechanism Of Action

History of Events

**Small Molecule to Inhibit HDAC1 and HDAC6 for Breast Cancer - Drug Profile**

Product Description

Mechanism Of Action

History of Events

**Small Molecule to Inhibit HDAC1, HDAC3 and HDAC6 for Lung Adenocarcinoma - Drug Profile**

Product Description

Mechanism Of Action

Small Molecule to Inhibit HDAC6 for Charcot-Marie-Tooth Disease Type II A - Drug Profile

Product Description

Mechanism Of Action

Small Molecule to Inhibit HDAC6 for Melanoma - Drug Profile

Product Description

Mechanism Of Action

Small Molecule to Inhibit HDAC6 for Sepsis - Drug Profile

Product Description

Mechanism Of Action

Small Molecules for Charcot-Marie-Tooth Disease - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit HDAC-6 for Autoimmune Disorders, Charcot-Marie-Tooth Disease and Pancreatic Cancer - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit HDAC6 for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Inhibit HDAC6 for Glioblastoma - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit HDAC6 for Immunology and Oncology - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit HDAC6 for Oncology - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit HDAC6 for Rett Syndrome - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Inhibit HDAC6 for Unspecified Indications - Drug Profile

Product Description

Mechanism Of Action

History of Events

SP-259 - Drug Profile

Product Description

Mechanism Of Action

Synthetic Peptides to Inhibit HDAC6 for Solid tumor, Fibrosis and Neurology - Drug Profile

Product Description

Mechanism Of Action

TN-301 - Drug Profile

Product Description

Mechanism Of Action

History of Events

vorinostat - Drug Profile

Product Description

Mechanism Of Action

History of Events

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Dormant Products

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Product Development Milestones

Featured News & Press Releases

Jul 06, 2022: Tenaya Therapeutics publishes preclinical data in science translational medicine detailing discovery of HDAC6 inhibitor for treatment of heart failure

May 20, 2022: Tenaya Therapeutics to present preclinical data on TN-301 HDAC6 inhibitor at European Society of Cardiology Heart Failure 2022 Conference

Apr 26, 2022: Jubilant Therapeutics doses first patient in phase I/II trial evaluating JBI-802, dual inhibitor of LSD1 and HDAC6, in patients with advanced solid tumors

Mar 11, 2022: AnnJi Pharmaceutical's HDAC6 selective inhibitor received "Grass Roots" support program award sponsored by Boehringer Ingelheim, Taiwan

Feb 01, 2022: Hillstream BioPharma announces acceptance of abstract at AACR 2022 annual meeting highlighting HSB-510, a novel quatramer-based, first-in-class dual inhibitor of HDAC6 and PI3K-delta downregulating c-myc expression

Jan 06, 2022: Jubilant Therapeutics announces FDA clearance of IND for JBI-802, a novel dual LSD1 and HDAC6 inhibitor, for treatment of solid tumors

Nov 18, 2021: Results from investigator-initiated phase II clinical study of remetinostat in patients with squamous cell carcinoma published

Sep 30, 2021: Jubilant Therapeutics announces successful completion of Pre-IND meeting with FDA for its novel dual LSD1 and HDAC6 inhibitor JB1-802

Aug 16, 2021: Medivir strengthens the business development potential of remetinostat through renegotiated multi-party agreement

Aug 12, 2021: Positive data from the remetinostat phase II study in basal cell carcinoma

published in Clinical Cancer Research

Aug 06, 2021: Medivir: First-in-class histone deacetylase inhibitor gel shows promise for the treatment of patients with basal cell carcinoma

Jul 29, 2021: Shuttle Pharma awarded a new patent for selective inhibitors for cancer treatment

Jul 13, 2021: Tenaya Therapeutics unveils preclinical research supporting product candidate for rare and prevalent heart disease indications at ESC Heart Failure 2021

May 20, 2021: Positive results from investigator-initiated phase II clinical study of remetinostat in patients with squamous cell carcinoma published

Dec 07, 2020: Jubilant Therapeutics announces efficacy and biomarker data at 62nd ASH Annual Meeting for its Novel Dual LSD1-HDAC6 Inhibitor for the Treatment of Hematological Cancers

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indications, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022

Number of Products under Investigation by Universities/Institutes, 2022

Products under Investigation by Universities/Institutes, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by Anji Pharmaceutical Co Ltd, 2022

Pipeline by ATP Biopharm, 2022

Pipeline by Augustine Therapeutics, 2022

Pipeline by Avstera Therapeutics Inc, 2022

Pipeline by Beijing Konruns Pharmaceutical Co Ltd, 2022

Pipeline by Bristol-Myers Squibb Co, 2022

Pipeline by Chong Kun Dang Pharmaceutical Corporation, 2022

Pipeline by Convalife, 2022

Pipeline by CStone Pharmaceuticals Co Ltd, 2022

Pipeline by Curis Inc, 2022

Pipeline by Eikonizo Therapeutics Inc, 2022

Pipeline by Guangdong Zhongsheng Pharmaceutical Co Ltd, 2022

Pipeline by Hillstream BioPharma Inc, 2022

Pipeline by Jubilant Therapeutics Inc, 2022

Pipeline by Kancera AB, 2022

Pipeline by Karus Therapeutics Ltd, 2022

Pipeline by KYAN Therapeutics Inc, 2022

Pipeline by Medivir AB, 2022

Pipeline by Merck & Co Inc, 2022

Pipeline by Mycovia Pharmaceuticals Inc, 2022

Pipeline by OnKure Inc, 2022

Pipeline by Oryzon Genomics SA, 2022

Pipeline by Quimatrix SL, 2022

Pipeline by Shuttle Pharmaceuticals Inc, 2022

Pipeline by SK Biopharmaceuticals Co Ltd, 2022

Pipeline by Starwise Therapeutics LLC, 2022

Pipeline by Suzhou GenHouse Pharmaceutical Co Ltd, 2022

Pipeline by Tenaya Therapeutics Inc, 2022

Dormant Products, 2022

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022



## I would like to order

Product name: Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/H4BA0E626FFFEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H4BA0E626FFFEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970